Ranbaxy Pharmaceuticals Canada Inc., in consultation with Health Canada, is recalling one batch of RAN-Gabapentin, a medication used to treat epilepsy, due to cross-contamination during the manufacturing process with Etodolac, a non-steroidal anti-inflammatory drug.
Via the Rapid Alert System from the German competent authority, the Agency for Medicinal Products and Medical Devices (HALMED) has received a notice on the suspected counterfeit batches of MabThera 100 mg concentrate for solution for infusion (batch: H0156B09, shelf-life: 05/2016) and MabThera 500 mg concentrate for solution for infusion (batch: H0721B04, shelf-life: 04/2016).
These batches reported as a suspected counterfeit have never been placed on the Croatian market.
More information is accessible under the link below.
An expert workshop "OTC medicines: the role of good classification in promoting medication safety and accessibility in Europe" organised by the Council of Europe’s European Directorate for the Quality of Medicines and Healthcare (EDQM) and the Agency for Medicinal Products and Medical Devices (HALMED) was held from 20 to 21 November 2014 in Zagreb. Nearly 100 participants from 19 countries in Europe, representing national and European competent drug authorities, ministries of health, healthcare professionals, patients’ organisations, the pharmaceutical industry and pharmaceutical wholesalers involved in classification of medicines as regard their supply.
Welcome speeches were held by Dr Susanne Keitel, PhD, the Director of EDQM, Dr Viola Macolić Šarinić, MD, PhD, the Head of HALMED and chair of the EDQM’s Committee of Experts on the Classification of Medicines as Regards their Supply (CD-P-PH/PHO).
The workshop was aimed at providing extended knowledge to participants and to familiarise them with the work of the Committee of Experts on the Classification of Medicines as regards their Supply (CD-P-PH/PHO), which annually issues recommendations to health authorities of European Pharmacopoeia member states for the classification of medicines and establishes good classification practices, and to collect feedback from the different stakeholders, including patient associations.
More information is accessible under the link below.
In future, we will comment on medicinal product names applied for (names of human medicines applied for under the mutual recognition (MRP) and decentralised procedures (DCP)) on Day 50 for MRP and on Day 100 for DCP with Denmark as concerned member state, and on Day 70 with Denmark as reference member state. This takes place at request from the pharmaceutical industry.
Subject to approval of name
However, this procedure is subject to the final approval of a name, because in the period until a marketing authorisation has been granted for a medicinal product, other medicinal product names may have been approved that can be confused with the medicinal product name applied for. Consequently, companies should note that the longer the clock stop period for an application, the greater the probability that the medicinal product name applied for has already been approved for another medicinal product, since it is not possible to reserve a name during the procedure.
In addition, other circumstances may also arise, such as changed naming practice, with the result that the name cannot be approved.
Regarding medicinal product names applied for under the purely national procedure, we will continue to comment on the name applied for both on Day 0 and when we send our Day 110 letter.
As regards veterinary medicines, we will also comment on the name applied for on Day 54 (MRP) as well as on Day 100 (DCP).
We only evaluate proposals for medicinal product names based on an actual application.
You can read more about the practice for the naming of medicines on our website.
The combination of low-dose aspirins and anticoagulant medicines can cause severe bleeding. Consequently, we have published new material describing the risk of this combination to patients with heart flutters and doctors.
About 100,000 Danes suffer from heart flutters, and every year between 15,000 and 20,000 new patients are diagnosed with heart flutters. Heart flutters can be dangerous, because there is an increased risk of blood clots. One out of five blood clots in the brain is caused by heart flutters. The risk of heart flutters increases with age, and around one in ten people above 75 years suffers from heart flutters.
Combination causes an increased risk of bleeding
Most patients suffering from heart flutters benefit from treatment with anticoagulant medicines like Marevan® (warfarin) that reduces the risk of blood clots. Around every tenth patient with heart flutters also takes Hjertemagnyl®, a low-dose aspirin, in combination with Marevan®.
For patients who are being treated with Marevan®, treatment with Hjertemagnyl® does not offer further protection against blood clots. However, the risk of bleeding increases.
Consequently, we have published new material describing the risk of this combination and what patients should be particularly aware of; the material is aimed at patients with heart flutters and doctors (in Danish only). For example, the publication advises patients to inform their doctor of the medicines they take, including over-the-counter medicine.
Links to the material (in Danish only)
Video om hjerteflimmer og bivirkninger ved samtidig brug af acetylsalicylsyre og warfarin
Patientfolder:"Hjerteflimmer" om atrieflimren, antikoagulansbehandling med warfarin, interaktioner samt de nye antikoagulerende lægemidler
Patientfolder: Hjerteflimmer og Hjertemagnyl om den forhøjede blødningsrisiko, der er ved samtidig behandling med acetylsalicylsyre og warfarin
Informationsfolder til læger: Information om antikoagulansbehandling ved atrieflimren